Innovation required in risk assessment of nanoparticles The currently existing models and techniques provide insufficient certainties in the assessment of the harmfulness of nanoparticles and nanomaterials to people and the environment.
Harmful substances in e-cigarettes assessed While e-cigarettes are less harmful to health than tobacco cigarettes, the vapour from an e-cigarette contains substances and chemical impurities in concentrations that could be detrimental to heal
Biobased alternatives to hormone disrupting substance in cash register receipts Chemicals made from vegetable or animal waste may be an alternative to the use of the substance Bisphenol A (BPA) in thermal paper. Thermal paper is widely used for cash register receipts.
RIVM and Olive Foundation open trading to mark the European Cervical Cancer Prevention Week January 20th, the Olive Foundation and RIVM opened AEX trading day in Amsterdam on the occasion of the 9th European Cervical Cancer Prevention Week.
Release of QMRAspot v2 for quantitative microbial risk assessment of drinking water RIVM has developed a new version of QMRAspot (2.0), a user-friendly computational tool to calculate the risk of becoming infected by pathogenic microorganisms in drinking water.
Promising biobased alternatives to substances of very high concern There are many possible biobased alternatives to substances of very high concern (SVHC). Some are even ready to be deployed right away.
RIVM investigates dangers of e-cigarette At the request of State Secretary Martin van Rijn (VWS), RIVM is carrying out an investigation into the safety of e-cigarettes.
RIVM film about nanomaterials RIVM contributes to the safe use of nanomaterials through research, alerts and policy consultations, and this work is demonstrated in a short informative film.
No more complementary vaccinations against measles for children aged six months The measles epidemic, the first case of which occurred in the Netherlands in May 2013, is coming to an end.
RIVM to research safe design for new nanoparticles RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.